Literature DB >> 9737816

Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus.

J H Park1, W I Lee, W H Yoon, Y D Park, J S Lee, M G Lee.   

Abstract

Because some physiological changes occurring in diabetes mellitus patients could alter the pharmacokinetics and pharmacodynamics of the drugs to treat the disease, the pharmacokinetics and pharmacodynamics of furosemide were investigated after intravenous (i.v.) and oral administration of the drug (6 mg per whole body weight) to control rats and alloxan-induced diabetes mellitus rats (AIDRs). After i.v. administration, the total body clearance (5.47 versus 7.05 mL min(-1) kg(-1)) was significantly slower in AIDRs and this was due to significantly slower renal clearance (2.35 versus 4.33 mL min(-1) kg(-1)) because the nonrenal clearance was comparable between two groups of rats. The 8 h urinary excretion of furosemide after i.v. administration decreased significantly (2280 versus 3760 microg) in AIDRs due to impaired kidney function; the glomerular filtration rate measured by creatinine clearance was significantly slower (2.86 versus 4.33 mL min(-1) kg(-1)) and both the plasma urea nitrogen (43.5 versus 17.3 mg dL(-1)) and kidney weight (0.953 versus 0.749% of body weight) increased significantly in AIDRs. This resulted in a significant decrease in the 8 h urine output per g kidney (17.8 versus 43.6 mL) in AIDRs. However, the 8 h diuretic efficiency was not significantly different between two groups of rats. After oral administration, the area under the plasma concentration-time curve from time 0 to 8 h decreased significantly in AIDRs (1200 versus 1910 microg x min mL(-1)) due to considerably decreased absorption of furosemide from gastrointestinal tract of AIDRs. After oral administration, the 8 h urine output per g kidney (18.6 versus 36.4 mL) also decreased significantly in the AIDRs due to significantly decreased 8 h urinary excretion of furosemide (405 versus 2210 microg), however, the 8 h diuretic efficiency increased significantly (127 versus 35.2 mL mg(-1)) in AIDRs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9737816     DOI: 10.1002/(sici)1099-081x(199809)19:6<357::aid-bdd114>3.0.co;2-g

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  8 in total

Review 1.  Drug disposition in pathophysiological conditions.

Authors:  Adarsh Gandhi; Bhagavatula Moorthy; Romi Ghose
Journal:  Curr Drug Metab       Date:  2012-11       Impact factor: 3.731

2.  Effect of CYP3A1(23) induction on clarithromycin pharmacokinetics in rats with diabetes mellitus.

Authors:  Yu C Kim; Joo H Lee; So H Kim; Myung G Lee
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

3.  Impact of Mrp2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats.

Authors:  Cuiping Chen; Dennis Scott; Elizabeth Hanson; Judy Franco; Edwin Berryman; Mario Volberg; Xingrong Liu
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

Review 4.  Strategies for preclinical pharmacokinetic investigation in streptozotocin-induced diabetes mellitus (DMIS) and alloxan-induced diabetes mellitus (DMIA) rat models: case studies and perspectives.

Authors:  Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-03-06       Impact factor: 2.441

5.  Study of the pharmacokinetic changes of Tramadol in diabetic rats.

Authors:  Hoda Lavasani; Behjat Sheikholeslami; Yalda H Ardakani; Mohammad Abdollahi; Lida Hakemi; Mohammad-Reza Rouini
Journal:  Daru       Date:  2013-03-07       Impact factor: 3.117

Review 6.  Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans.

Authors:  Nadia O Bamfo; Chelsea Hosey-Cojocari; Leslie Z Benet; Connie M Remsberg
Journal:  Pharm Res       Date:  2021-07-12       Impact factor: 4.580

7.  Evaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo.

Authors:  Im-Sook Song; Tae Yeon Kong; Hyeon-Uk Jeong; Eun Nam Kim; Soon-Sang Kwon; Hee Eun Kang; Sang-Zin Choi; Miwon Son; Hye Suk Lee
Journal:  BMC Complement Altern Med       Date:  2014-07-17       Impact factor: 3.659

Review 8.  Imbalance of Drug Transporter-CYP450s Interplay by Diabetes and Its Clinical Significance.

Authors:  Yiting Yang; Xiaodong Liu
Journal:  Pharmaceutics       Date:  2020-04-11       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.